Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma
Maria João Baptista(Josep Carreras Leukaemia Research Institute), José‐Tomás Navarro(Universitat Autònoma de Barcelona), Pau Abrisqueta(Universitat Autònoma de Barcelona), Silvia Montoto(Queen Mary University of London), Mireia Morgades(Josep Carreras Leukaemia Research Institute), José Luís Mate(Universitat Autònoma de Barcelona), Blanca González‐Farré(Hospital Clínic de Barcelona), Miguel Alcoceba(Instituto de Investigación Biomédica de Salamanca), Maria Calaminici(Queen Mary University of London), Carlos García‐Ballesteros(Hospital Arnau de Vilanova), Eva González‐Barca(Institut Català d'Oncologia), Javier Briones(Hospital de Sant Pau), Ferran Vall‐Llovera(Mútua Terrassa), María José Terol(Hospital Clínico Universitario de Valencia), John G. Gribben(Queen Mary University of London), José M. Moraleda(Centro Regional de Hemodonación), Gustavo Tapia(Hospital Universitari Germans Trias i Pujol), Eugènia Abella(Hospital Del Mar), Juan‐Manuel Sancho(Hospital Universitari Germans Trias i Pujol), Josep‐María Ribera(Universitat Autònoma de Barcelona), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Ana M Muñoz‐Mármol(Universitat Autònoma de Barcelona), Josep Muncunill(Universitat Autònoma de Barcelona), Pilar Miralles(Hospital General Universitario Gregorio Marañón), Iván Dlouhy
Cited by 10
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k